首页 › 基金 › Duquesne Family Office LLC › NAMS

Duquesne Family Office LLC 对 NAMS 的持仓历史

NEWAMSTERDAM PHARMA COMPANY · 医疗保健

Duquesne Family Office LLC 在 Q3 2026 的 13F 申报中披露持有 NAMS(NEWAMSTERDAM PHARMA COMPANY)3,357,146 股,市值约 US$81.6M,约占其申报组合的 2.17%,在其申报持仓中市值排名第 12 位。 Duquesne Family Office LLC 最近 9 个申报季度中有 9 个季度披露了 NAMS 持仓,最早可追溯至 Q3 2024。

最新持仓 (Q3 2026)3.36M 股
申报持仓市值$81.65M
组合权重2.17%
首次申报Q3 2024
最近变动增持
更新于2026-11-17

最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR

Duquesne Family Office LLC 对 NAMS 的持仓演变

Duquesne Family Office LLC 于 Q3 2024 首次披露 NAMS 持仓:287,535 股(约 US$4.8M)。 该持仓在 Q4 2025 达到峰值 3,070,146 股,市值约 US$107.7M。 在 9 次申报中,Duquesne Family Office LLC 5 次增持、0 次减持、3 次保持不变。 最近一期申报(Q3 2026)显示持股 3,357,146 股、市值约 US$81.6M,环比增持 287,000 股。。 持仓曾出现大幅变动:Q1 2025 增持约 178% (随后一个季度股价下跌 8%)、Q3 2025 增持约 131% (随后一个季度股价上涨 23%)、Q4 2025 增持约 60% (随后一个季度股价下跌 9%)。

逐季持仓明细

季度股数金额变化
Q3 2024 287.54K $4.77M 新进
Q4 2024 287.54K $7.39M 持有
Q1 2025 800.36K $16.38M 增持
Q2 2025 832.17K $15.07M 增持
Q3 2025 1.92M $54.71M 增持
Q4 2025 3.07M $107.70M 增持
Q1 2026 3.07M $98.28M 持有
Q2 2026 3.07M $104.05M 持有
Q3 2026 3.36M $81.65M 增持

折线上的点按变动类型着色;缺失季度表示该季未申报持仓。

关于 NAMS 与 13F 数据

NAMS(NEWAMSTERDAM PHARMA COMPANY)属于医疗保健行业。我们追踪的基金中还有 34 只申报持有 NAMS,申报仓位最大的包括:Frazier Life Sciences Management, L.P. (US$461.8M), RA CAPITAL MANAGEMENT, L.P. (US$232.3M), FCPM III SERVICES B.V. (US$206.5M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 NAMS 的基金

查看 NAMS 的全部基金持有人 →

常见问题

How long has Duquesne Family Office LLC held NAMS?

Duquesne Family Office LLC has disclosed NAMS holdings in 9 of the last 9 reported quarters, going back to Q3 2024.

What is Duquesne Family Office LLC's current position in NAMS?

As of Q3 2026, Duquesne Family Office LLC holds 3.36M shares of NAMS (NEWAMSTERDAM PHARMA COMPANY), valued at $81.65M, representing 2.17% of its reported portfolio and ranking #12.

Has Duquesne Family Office LLC been buying or selling NAMS?

In the latest 13F filing (Q3 2026), Duquesne Family Office LLC increased its position in NAMS. The position peaked in Q4 2025 at 3.07M shares.

Which other funds hold NAMS?

Other major institutional holders of NAMS include Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., FCPM III SERVICES B.V., among 34 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.